Focusing on early detection and disease preventionOver 150 clinicians, scientists, and staff will be pioneering new treatments and cures and working on disease prevention strategies in the new Robert H.N Ho Research Centre. The facility, adjacent to the Jack Bell Research Centre, is home to three internationally-recognized health research programs: the Centre for Hip Health and Mobility; the Ovarian Cancer Research Program, and an expansion of the Vancouver Prostate Centre.
Vancouver, B.C. – The Provincial Health Services Authority (PHSA) is pleased to announce that its Centre for Translational and Applied Genomics (CTAG) has been granted full accreditation status by the College of American Pathologists (CAP). CAP is the world’s largest association composed exclusively of pathologists certified by the American Board of Pathology and is widely considered the leader in laboratory quality assurance. CTAG, a division of PHSA Laboratories, is a self-funded translational research facility, focusing on cutting-edge research and development.
Vancouver, British Columbia — Two Vancouver researchers are tackling the deadliest forms of prostate cancer, the most commonly diagnosed male cancer in Canada, using a brand new field of genomics called computational chemogenomics. This new approach uses computer modeling in virtual 3D to predict how different chemicals or drugs will affect cancer tumours.The project, titled “Methods of Chemical Genomics” has received $324,000 in funding, with $161,500 from Genome BC and the rest from other partners including the Canadian Institutes of Health Research and the Vancouver Prostate Centre.
The Vancouver Prostate Centre today announced a one-year collaborative project with Novartis Pharmaceutical Corporation. The project will use cutting-edge technology to identify and validate the molecular targets that predict cancer sensitivity or insensitivity to specific inhibitors.
The results from a Phase II clinical trial of OGX-011, lead by Dr. Kim Chi, have been published in the Journal of Clinical Oncology. OGX-011 was developed at the Vancouver Prostate Centre, and is now moving to Phase III trials.Further details describing the development of OGX-011 were recently the subject of an article in the Vancouver Sun.
Two Vancouver-based “Centres of Excellence in Commercialization in Research” Leverage Resources and Expertise to Develop Anti-Cancer TherapeuticsVANCOUVER, BC – The Centre for Drug Research and Development (CDRD) and the Vancouver Prostate Centre (VPC) today announced that they have signed a preferred collaboration agreement as the two organizations jointly strive to accelerate the discovery, development and commercialization of anti-cancer therapeutics.“Knowing that our two organizations hold similar mandates, this collaboration with CDRD ensures that we are maximizing our resources to inc
OSAKA, JPN – The BC Cancer Agency and the Vancouver Protate Centre announced a formal agreement with Japan-based Takeda Pharmaceutical Co. Ltd. for new drug treatments to fight breast, ovarian and prostate cancers.The agreement is expected to bring almost $1 million in new cancer research funding to British Columbia.“We have been able to attract this investment in cancer research to British Columbia because of the unique integration of world-class care and research being done by the BC Cancer Agency and the Vancouver Prostate Centre,” said Premier Gordon Campbell.
An international project using exotic wildlife to find cures for prostate cancer and other fatal diseases has received major Queensland Government funding.Queensland Premier Anna Bligh has today announced that $1.53 million Smart Futures Fund grant to support a new $6.2 million Queensland-British Columbia Drug Discovery Alliance between Griffith University’s Eskitis Institute, the Australian Prostate Cancer Research Centre, and two British Columbia research centres -- the Centre for Drug Research and Development and the Vancouver Prostate Centre.The breakthrough project’s ultimate goal is t
VANCOUVER, COLOMBIE-BRITANNIQUE – Le Vancouver Prostate Centre a annoncé la prolongation de son partenariat avec AstraZeneca, ce qui lui permettra de recevoir un montant de 700 000 $ sur deux ans pour financer la recherche sur le cancer de la prostate réfractaire au traitement.L’objectif de cette recherche, dont la coordination est assurée par le Vancouver Prostate Centre, un centre d’excellence quant à la commercialisation et à la recherche, est d’évaluer les petites molécules découvertes par AstraZeneca qui ciblent les récepteurs des androgènes et le cycle de croissance cellulaire, afin d